Docket No. PJ3732USW US National Phase of PCT77700/05200 Preliminary Amendment

information. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date:

29 Jan 2002

James P. Riek

Attorney of Record Reg. No. 39009

GlaxoSmithKline Corporate Intellectual Property Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398

Telephone: 919-483-8022

Fax: 919-483-7988

Docket No. PJ3732USW
US National Phase of PC177700/05200
Preliminary Amendment

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

On the first line of the specification, after the Title, the following text was added

--This application is filed pursuant to 35 U.S.C. §371 as a United States National Phase Application of International Application No. PCT/ JP00/05200 filed 3 August, 2000, which claims priority from GB 9918559.7 filed 7 August 1999 in the United Kingdom.--